Significant biosimilar activities this week include:
On 30 Mar 2020, Biocad announced it had received registration certificates from Bosnia and Herzegovina for Acellbia® (rituximab) and Herticad® (trastuzumab), with a launch expected in 2020.
On 30 March 2020, in response to CoVid-19, Genentech announced it would extend physician payment terms for Lucentis® (ranibizumab) purchases to 120 days, up from the previous 60 day term. These new terms will be implemented from 01 April, 2020, as well as retroactively for Lucentis® purchased on or after March 1, 2020.
On 01 April 2020, a new study reported that Truxima® (rituximab) is comparable to the originator in terms of efficacy and safety in the treatment of multiple sclerosis. Rituximab is not currently indicated for multiple sclerosis but it is used off-label in some cases and is under investigation as a potential treatment.
On 02 April 2020, Pfizer announced EC approval of Ruxience® (Rituximab) for the treatment of non-hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.